The life sciences sector is at a crossroads as the FDA updates quality management standards. AI is now expected, and the FDA’s January 2025 draft guidance outlines its evaluation and implementation. Successful adoption depends on three key questions.
Safe and Sane: Understanding the FDA’s Risk-Based Approach to AI
Related Posts
Quality Welcomes New Member to the Team
Quality announced Koala T. Bear as its brand ambassador and representative to the quality community.
The Singularity – The Promise of Technology?
The singularity—or more accurately, the technological singularity—“is a hypothetical future point in time at which technological growth becomes…
April 2026 US Cutting Tool Shipments Totaled $258.9M, Up 21.1% From April 2025
Shipments of cutting tools, measured by the Cutting Tool Market Report, a collaboration between AMT – The Association…